Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib vs Erlotinib in Advanced NSCLC
NCT00769067Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2008
- Primary completion
- Oct 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 2 trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Nov 2008; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00769067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769067.